Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Change in Inventory (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Change in Inventory for 3 consecutive years, with $123000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Inventory rose 130.37% to $123000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $50000.0, a 133.33% increase, with the full-year FY2025 number at $50000.0, up 133.33% from a year prior.
  • Change in Inventory was $123000.0 for Q4 2025 at Lexicon Pharmaceuticals, up from -$10000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $172000.0 in Q2 2023 to a low of -$405000.0 in Q4 2024.
  • A 3-year average of $25545.5 and a median of $51000.0 in 2024 define the central range for Change in Inventory.
  • Peak YoY movement for Change in Inventory: plummeted 1000.0% in 2024, then skyrocketed 130.37% in 2025.
  • Lexicon Pharmaceuticals' Change in Inventory stood at $45000.0 in 2023, then tumbled by 1000.0% to -$405000.0 in 2024, then surged by 130.37% to $123000.0 in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Change in Inventory are $123000.0 (Q4 2025), -$10000.0 (Q3 2025), and -$33000.0 (Q2 2025).